An observational study in Healthcare-associated Infections, Quality Culture and Leadership in Intensive Care and Infection Prevention and Control, sponsored by Yeliz Sapulu Alakan. Not yet recruiting. Open to participants aged Up to 125 Years. Per ClinicalTrials.gov, last updated 2026-08-24.
Sponsored by Yeliz Sapulu Alakan · Observational
This study aims to examine intensive care nurses' perceptions of leadership in quality culture for infection prevention and to investigate antimicrobial resistance indicators at the intensive care unit level. Healthcare-associated infections (HAIs) remain a major global patient safety problem and are associated with prolonged hospital stays, increased healthcare costs, and higher mortality. The increasing prevalence of antimicrobial resistance (AMR) further complicates infection prevention and patient care.
Intensive care units are particularly vulnerable to healthcare-associated infections and antimicrobial resistance because of the high frequency of invasive procedures, the vulnerability of critically ill patients, and the extensive use of broad-spectrum antibiotics. Nurses play a central role in infection prevention and antimicrobial stewardship because they are continuously involved in patient care. However, previous studies have reported a gap between nurses' knowledge of infection prevention and adherence to recommended practices in clinical settings. Organizational culture and leadership may contribute to this gap.
Most previous studies have focused on healthcare professionals' self-reported perceptions of infection prevention. However, limited evidence is available regarding the relationship between nurses' perceptions of leadership and quality culture and objective antimicrobial resistance indicators at the intensive care unit level. Therefore, this study will assess nurses' perceptions using the Leadership in Quality Culture for Infection Prevention (LCQ-IP) instrument and examine their relationship with retrospective microbiological data from the participating intensive care units, including antimicrobial resistance rates and resistance profiles. The findings may provide evidence on the role of organizational leadership and quality culture in infection prevention and antimicrobial resistance management in intensive care settings.
285 studies on the registry are indexed under Cross Infection; 48 are open to participants now.
This study's planned enrollment of 127 is below the median of 351 across 115 observational studies indexed under Cross Infection.
Browse Cross Infection studies →This is the only study on the registry with Yeliz Sapulu Alakan as lead sponsor.
Counted across the registry records on this site, refreshed daily.
The study population will consist of nurses actively working in intensive care units in participating hospitals in Bursa and Iğdır, Türkiye. Eligible participants will be nurses who have been actively working in an intensive care unit for at least 1 year and who voluntarily agree to participate in the study. Student nurses, nursing interns, nurses working temporarily or on a rotational basis in intensive care units, and nurses with less than 1 year of intensive care experience will be excluded.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Intensive Care Nurses and Intensive Care Units in Bursa
Intensive Care Nurses and Intensive Care Units in Iğdır
Leadership in Quality Culture for Infection Prevention (LCQ-IP) score among intensive care nurses
Leadership for a culture of quality in infection prevention will be assessed using the Turkish version of the Leading a Culture of Quality for Infection Prevention Scale. The scale consists of 16 items rated on a 5-point Likert scale. Total scores range from 16 to 80, with higher scores indicating a more positive perception of leadership for a culture of quality in infection prevention.
Time frame: Baseline
Antimicrobial Susceptibility Profiles of Bacterial Isolates from Intensive Care Units
Time frame: The 1-year period preceding study enrollment
No study locations are listed for this record.
Plan to share: No — Individual participant-level data will not be shared with other researchers. The study will use data collected from intensive care nurses and retrospective, unit-level microbiological and antimicrobial resistance data. Data will not be shared because of ethical, privacy, and confidentiality considerations. Only aggregated and de-identified results will be reported.
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Nov 2026, 2 months later.
Of 56 non-industry observational studies under Cross Infection, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 65. This study's planned 2 months is below that.
Counting every sponsor, half of 56 studies reached it within 28 months; a quarter within 17 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.